Diabetic dyslipidaemia and residual risk in the era of LDL control

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
The effect of icosapent ethyl on CV events in metabolic syndrome
Diabetes
The effect of icosapent ethyl on CV events in metabolic syndrome
- Michael Miller, MD
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
Kidney Disease
A practical look at cardiorenal protection for CKD in T2D: Applying recent data
- Carolyn Lam, MD, PhD
- Maria Luiza Caramori, MD, PhD
- Ana Maria Cebrián-Cuenca, MD, PhD
- Pam R. Taub, MD, FACC, FASPC
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD